Semaglutide vs. Tirzepatide in 2026: Which One Is Right for You?

The first head-to-head trial is in. Tirzepatide produced 47% more weight loss than semaglutide. But the full picture — including oral options, pricing, and availability — makes the choice less obvious than you'd think.

The two most popular GLP-1 medications now have head-to-head clinical data. SURMOUNT-5 directly compared tirzepatide (Zepbound) against semaglutide (Wegovy) in adults with obesity — and tirzepatide came out ahead on weight loss. But more weight loss doesn't automatically mean it's the right choice for everyone. NEJM

Here's a comprehensive, updated comparison for 2026 — including the new oral options that didn't exist a year ago.

The Head-to-Head Data: SURMOUNT-5

When Semaglutide Might Be the Better Choice

You want a pill instead of an injection. Semaglutide is currently the only GLP-1 available as an FDA-approved oral medication for weight loss. If needle aversion is your primary barrier, this solves it.

Heart health is a priority. Semaglutide is the only obesity medication with an FDA-approved cardiovascular risk reduction indication, based on the SELECT trial's 20% reduction in major adverse cardiovascular events. If you have existing heart disease or high cardiovascular risk, this label matters.

Price sensitivity. With oral Wegovy starting at $149/month, semaglutide currently offers the lowest brand-name entry point for GLP-1 treatment.

Longer track record. Semaglutide has been on the market longer, which means more real-world safety data and broader insurance coverage.

When Tirzepatide Might Be the Better Choice

Maximum weight loss is your goal. The SURMOUNT-5 data is clear — tirzepatide produces significantly more weight loss than semaglutide. If you're starting at a higher BMI and need the most effective option available, tirzepatide delivers.

You have sleep apnea. Tirzepatide is the only GLP-1 with an FDA-approved indication for obstructive sleep apnea. If this is a co-occurring condition, Zepbound addresses both at once.

Blood sugar control is important. The dual GIP/GLP-1 mechanism gives tirzepatide an edge in A1C reduction for patients with type 2 diabetes. In SURPASS trials, it produced greater glucose improvements than semaglutide.

What About Compounded Versions?

Both semaglutide and tirzepatide are available as compounded formulations through licensed telehealth providers at lower price points than brand-name options. Compounded medications are not FDA-approved, but when sourced from legitimate, state-licensed compounding pharmacies, they offer an affordable path to GLP-1 treatment for patients who might otherwise not be able to access these medications.

If you're considering the compounded route, the key factors to evaluate are: Is the pharmacy state-licensed? Do they source their active pharmaceutical ingredients from FDA-registered manufacturers? Is there a licensed prescriber involved in your care? If the answer to all three is yes, you're working within the established legal framework.

Explore GLP-1 Providers

Ready to get started? These verified telehealth providers offer GLP-1 programs with medical oversight and home delivery:

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content or provider selection.